Serum BCMA May Help Predict Outcomes, Monitor Disease in Multiple Myeloma
James R. Berenson, MD, discusses serum BCMA and markers for predicting outcomes and monitoring disease in patients with multiple myeloma.
Related Articles
PM8002/BNT327 Combo Improves Efficacy and Safety in Metastatic TNBC
Data from a phase 1b/2 study show a 78.6% ORR in patients with metastatic triple-negative breast cancer treated with PM8002/BNT327 plus nab-paclitaxel.
Patients with heart disease may be at increased risk for advanced breast cancer
Cardiovascular disease (CVD) and cancer are the two leading causes of death in the U.S. According to researchers from The University of Texas MD Anderson…
FDA approves nivolumab and hyaluronidase-nvhy for subcutaneous injecti
FDA approves nivolumab and hyaluronidase-nvhy for subcutaneous injection
Submit Late-Breaking Abstracts | Society of Gynecologic Oncology
The call for late-breaking abstracts for the Society of Gynecologic Oncology (SGO) 2025 Annual Meeting on Women’s Cancer is now open! The deadline for submissions…
FDA Grants Priority Review to Avutometinib Plus Defactinib for KRAS+ Recurrent Low-Grade Serous Ovarian Cancer
The FDA has granted priority review to the NDA for avutometinib plus defactinib in KRAS-mutant recurrent low-grade serous ovarian cancer.
Registration
Register for the AACR Annual Meeting 2025, taking place April 25-30 in Chicago, Illinois.
Hema Now: Episode 7: Decoding T Cells and Advancing Immunology
Discover the immunobiology of Myelodysplastic syndrome and Aplastic anaemia, the role of CD4+ T cells in myeloid malignancies, and more. Listen today
ClinicalTrials.gov
Hide glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.
Sustained remission at long term follow-up in adolescents and young adults with chronic primary immune thrombocytopenia
Key PointsAt 24-, 36-, and 48-month FU, 10% of AYAs with chronic ITP attain yearly SCROT.Higher platelet counts and lower use of rescue therapy during…
MARIPOSA Trial Shows PFS Benefit With or Without CNS Disease in NSCLC
During a Case-Based Roundtable® event, Joshua K. Sabari, MD, discussed the mechanism of action of amivantamab and the MARIPOSA trial in patients with EGFR-mutated non–small…
